Serum markers of hepatic fibrogenesis in chronic hepatitis type C treated with alfa-2A interferon. 1994

A Gallorini, and M Plebani, and P Pontisso, and L Chemello, and M Masiero, and G Mantovani, and A Alberti
Istituto di Medicina Clinica, Università di Padova, Italy.

Hepatic fibrogenesis is a dynamic process which characterizes the course of chronic hepatitis. It has stimulated interest in the possible effect of interferon therapy on liver fibrosis. We have evaluated a panel of serum markers of fibrogenesis, namely N-terminal procollagen III peptide (PII-INP), C-terminal procollagen I peptide (PICP), laminin and hyaluronate in 35 patients with chronic hepatitis type C, before, during and after interferon treatment. Before treatment, PIIINP was elevated in 8.5%, 44% and 71% of patients with chronic persistent hepatitis, chronic active hepatitis and cirrhosis, respectively, while the corresponding figures for PICP were 0%, 50% and 46%, and for laminin 16.5%, 70% and 71%; hyaluronate was elevated in only five out of seven patients with cirrhosis. Patients with high PIIINP levels at presentation and a persistent response to treatment showed persistent normalization of this parameter, which was not observed in non-responders. In contrast, the other markers showed no significant correlation with interferon response. These results indicate that PIIINP correlates with interferon response in chronic hepatitis type C.

UI MeSH Term Description Entries
D007797 Laminin Large, noncollagenous glycoprotein with antigenic properties. It is localized in the basement membrane lamina lucida and functions to bind epithelial cells to the basement membrane. Evidence suggests that the protein plays a role in tumor invasion. Merosin,Glycoprotein GP-2,Laminin M,Laminin M Chain,Chain, Laminin M,Glycoprotein GP 2,M Chain, Laminin
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008103 Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules. Cirrhosis, Liver,Fibrosis, Liver,Hepatic Cirrhosis,Liver Fibrosis,Cirrhosis, Hepatic
D008297 Male Males
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011347 Procollagen A biosynthetic precursor of collagen containing additional amino acid sequences at the amino-terminal and carboxyl-terminal ends of the polypeptide chains. Protocollagen,Procollagen Type M
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006521 Hepatitis, Chronic INFLAMMATION of the LIVER with ongoing hepatocellular injury for 6 months or more, characterized by NECROSIS of HEPATOCYTES and inflammatory cell (LEUKOCYTES) infiltration. Chronic hepatitis can be caused by viruses, medications, autoimmune diseases, and other unknown factors. Chronic Hepatitis,Cryptogenic Chronic Hepatitis,Hepatitis, Chronic, Cryptogenic,Hepatitis, Chronic Active,Hepatitis, Chronic Persistent,Chronic Active Hepatitis,Chronic Hepatitis, Cryptogenic,Chronic Persistent Hepatitides,Chronic Persistent Hepatitis,Hepatitis, Cryptogenic Chronic

Related Publications

A Gallorini, and M Plebani, and P Pontisso, and L Chemello, and M Masiero, and G Mantovani, and A Alberti
February 1997, Recenti progressi in medicina,
A Gallorini, and M Plebani, and P Pontisso, and L Chemello, and M Masiero, and G Mantovani, and A Alberti
July 1996, Hepatology (Baltimore, Md.),
A Gallorini, and M Plebani, and P Pontisso, and L Chemello, and M Masiero, and G Mantovani, and A Alberti
July 2001, Zeitschrift fur Gastroenterologie,
A Gallorini, and M Plebani, and P Pontisso, and L Chemello, and M Masiero, and G Mantovani, and A Alberti
June 1999, Journal of gastroenterology,
A Gallorini, and M Plebani, and P Pontisso, and L Chemello, and M Masiero, and G Mantovani, and A Alberti
June 1996, Hepatology (Baltimore, Md.),
A Gallorini, and M Plebani, and P Pontisso, and L Chemello, and M Masiero, and G Mantovani, and A Alberti
February 2016, Journal of pediatric gastroenterology and nutrition,
A Gallorini, and M Plebani, and P Pontisso, and L Chemello, and M Masiero, and G Mantovani, and A Alberti
January 2016, Journal of pediatric gastroenterology and nutrition,
A Gallorini, and M Plebani, and P Pontisso, and L Chemello, and M Masiero, and G Mantovani, and A Alberti
January 1994, The New England journal of medicine,
A Gallorini, and M Plebani, and P Pontisso, and L Chemello, and M Masiero, and G Mantovani, and A Alberti
April 2014, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology,
A Gallorini, and M Plebani, and P Pontisso, and L Chemello, and M Masiero, and G Mantovani, and A Alberti
January 2005, Przeglad epidemiologiczny,
Copied contents to your clipboard!